Epoxyeicosatrienoic acids: Formation, metabolism and potential role in tissue physiology and pathophysiology

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 7, 2009, Pages 757-771

  Kaspera, Rüdiger ^a   Totah, Rheem A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Arachidonic acid; CYP; CYP2C8; CYP2J2; EETs

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450 2C; CYTOCHROME P450 2J2; EPOXYICOSATRIENOIC ACID;

ARACHIDONIC ACID METABOLISM; BRAIN TISSUE; CARDIOVASCULAR SYSTEM; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXCRETION; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; HOMEOSTASIS; HUMAN; INTESTINE; KIDNEY; LIPID STORAGE; LIVER; LUNG PARENCHYMA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TISSUE DISTRIBUTION; TUMOR;

ANIMALS; EICOSANOIDS; HUMANS; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 67650717705     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902932923     Document Type: Review

References (102)

1. Fitzpatrick FA, Soberman R. Regulated formation of eicosanoids. J Clin Invest 2001;107(11):1347-1351
2. Karara A, Dishman E, Jacobson H, et al. Arachidonic acid epoxygenase. Stereochemical analysis of the endogenous epoxyeicosatrienoic acids of human kidney cortex. FEBS Lett 1990;268(1):227-230
3. Capdevila JH, Vijaykumar RH, Falck JR. Cytochrome P450 and the mechanism an bioactivation of arachidonic acid and eicosanoids. In: Montellano PROD, editor, Cytochrome P450: structure, mechanism, and biochemistry. 3rd ed. New York: Kluwer Academics/Plenum Publishers, 2004. p. 531-545
4. Fer M, Dreano Y, Lucas D, et al. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys 2008;471(2):116-125
5. Fulton D, Falck JR, McGiff JC, et al. A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol. J Lipid Res 1998;39(8):1713-1721 (Pubitemid 28377937)
6. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007;292(3):C996-1012 (Pubitemid 46442641)
7. Chen JK, Chen J, Imig JD, et al. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J Biol Chem 2008;283(36):24514-24524
8. Yang W, Tuniki VR, Anjaiah S, et al. Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 2008;324(3):1019-1027
9. de Morais SM, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun 1993;194(1):194-201 (Pubitemid 23237919)
10. Wei S, Brittin JJ, Falck JR, et al. Chiral resolution of the epoxyeicosatrienoic acids, arachidonic acid epoxygenase metabolites. Anal Biochem 2006;352(1):129-134
11. Singh H, Schwartzman ML. Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep 2008;60(1):29-37 (Pubitemid 351586540)
12. Jiang H, McGiff JC, Quilley J, et al. Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells. J Biol Chem 2004;279(35):36412-36418 (Pubitemid 39128980)
13. Karara A, Wei S, Spady D, et al. Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 1992;182(3):1320-1325
14. Widstrom RL, Norris AW, Van Der Veer J, Spector AA. Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry 2003;42(40):11762-11767 (Pubitemid 37243637)
15. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294(5548):1871-1875 (Pubitemid 33101574)
16. Gauthier KM, Baewer DV, Hittner S, et al. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am J physiol 2005;288(3):H1344-351 (Pubitemid 40270043)
17. Labitzke EM, Diani-Moore S, Rifkind AB. Mitochondrial P450-dependent arachidonic acid metabolism by TCDD-induced hepatic CYP1A5; conversion of EETs to DHETs by mitochondrial soluble epoxide hydrolase. Arch Biochem Biophys 2007;468(1):70-81 (Pubitemid 350087840)
18. Zeldin DC, Kobayashi J, Falck JR, et al. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 1993;268(9):6402-6407 (Pubitemid 23099336)
19. Moreland KT, Procknow JD, Sprague RS, et al. Cyclooxygenase (COX)-1 and COX-2 participate in 5,6-epoxyeicosatrienoic acid-induced contraction of rabbit intralobar pulmonary arteries. J Pharmacol Exp Ther 2007;321(2):446-454 (Pubitemid 46624502)
20. Tran KL, Aronov PA, Tanaka H, et al. Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. Biochemistry 2005;44(36):12179-12187 (Pubitemid 41285716)
21. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004;43(1):55-90 (Pubitemid 37433867)
22. Spearman ME, Prough RA, Estabrook RW, et al. Novel glutathione conjugates formed from epoxyeicosatrienoic acids (EETs). Arch Biochem Biophys 1985;242(1):225-230 (Pubitemid 16224090)
23. Fang X, Hu S, Xu B, et al. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Am J Physiol 2006;290(1):H55-63
24. Fornage M, Boerwinkle E, Doris PA, et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 2004;109(3):335-339 (Pubitemid 38133900)
25. Fang X, Kaduce TL, Weintraub NL, et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 2001;276(18):14867-14874 (Pubitemid 37373365)
26. Fang X, Weintraub NL, McCaw RB, et al. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol 2004;287(6):H2412-20 (Pubitemid 39557109)
27. Fang X, Kaduce TL, Weintraub NL, et al. Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res 1996;79(4):784-793 (Pubitemid 26317826)
28. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001;276(39):36059-36062 (Pubitemid 37384204)
29. Suzuki S, Oguro A, Osada-Oka M, et al. Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J Pharmacol Sci 2008;108(1):79-88
30. Inceoglu B, Schmelzer KR, Morisseau C, et al. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 2007;82(1-4):42-49 (Pubitemid 44880165)
31. Paine MF, Oberlies NH. Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 2007;3(1):67-80 (Pubitemid 47307455)
32. Gaedigk A, Baker DW, Totah RA, et al. Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther 2006;319(2):523-532 (Pubitemid 44776355)
33. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004;52(4):447-454 (Pubitemid 38420379)
34. Imaoka S, Hashizume T, Funae Y. Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug Metab Pharmacokinet 2005;20(6):478-484
35. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 1998;353(1):16-28
36. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-423
37. Daikh BE, Lasker JM, Raucy JL, Koop DR. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 1994;271(3):1427-1433 (Pubitemid 24382654)
38. Yamazaki H, Okayama A, Imai N, et al. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 2006;36(12):1201-1209 (Pubitemid 44963419)
39. Lundblad MS, Stark K, Eliasson E, et al. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005;327(4):1052-1057 (Pubitemid 40137975)
40. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11(7):597-607 (Pubitemid 32953585)
41. Zeldin DC, Foley J, Ma J, et al. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol 1996;50(5):1111-1117 (Pubitemid 26384849)
42. Fife KL, Liu Y, Schmelzer KR, et al. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther 2008;327(3):707-715
43. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401(6752):493-497 (Pubitemid 29470209)
44. Wu S, Moomaw CR, Tomer KB, et al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996;271(7):3460-3468 (Pubitemid 26065653)
45. Roman RJ. P-450 Metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-185 (Pubitemid 34654217)
46. Delozier TC, Kissling GE, Coulter SJ, et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 2007;35(4):682-688
47. Fleming I, Michaelis UR, Bredenkotter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001;88(1):44-51 (Pubitemid 32064081)
48. Fleming I. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Trends Pharmacol Sci 2007;28(9):448-452 (Pubitemid 47376754)
49. Larsen BT, Gutterman DD, Sato A, et al. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ Res 2008;102(1):59-67
50. Viswanathan S, Hammock BD, Newman JW, et al. Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. J Am Coll Nutr 2003;22(6):502-510 (Pubitemid 38010016)
51. Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 2004;348(1-2):57-61 (Pubitemid 39209001)
52. Hercule HC, Schunck WH, Gross V, et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009;29(1):54-60;
53. Zhang L, Cui Y, Geng B, Zeng X, Tang C. 11,12-Epoxyeicosatrienoic acid activates the L-arginine/nitric oxide pathway in human platelets. Mol Cell Biochem 2008;308(1-2):51-56
54. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005;433(2):413-420 (Pubitemid 39592795)
55. Batchu SN, Law E, Brocks DR, et al. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 2009;46(1):67-74
56. Marden NY, Fiala-Beer E, Xiang SH, Murray M. Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. Biochem J 2003;373(Pt 3):669-680 (Pubitemid 36981077)
57. Yang B, Graham L, Dikalov S, et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001;60(2):310-320 (Pubitemid 32678296)
58. Lu T, Ye D, Wang X, et al. Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol 2006;575(Pt 2):627-644 (Pubitemid 44270186)
59. Behm DJ, Ogbonna A, Wu C, et al. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 2009;328(1):231-239
60. Spiecker MD, Hankeln H, Soufi T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP 2J2. Circulation 2004;110(15):2132-2136 (Pubitemid 39372490)
61. Jiang H. Erythrocyte-derived epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 2007;82(1-4):4-10
62. Raunio H, Hakkola J, Hukkanen J, et al. Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl 1998;20:465-469
63. Kiss L, Roder Y, Bier J, et al. Direct eicosanoid profiling of the hypoxic lung by comprehensive analysis via capillary liquid chromatography with dual online photodiode-array and tandem mass-spectrometric detection. Anal Bioanal Chem 2008;390(2):697-714
64. Alvarez DF, Gjerde EA, Townsley MI. Role of EETs in regulation of endothelial permeability in rat lung. Am J Physiol Lung Cell Mol Physiol 2004;286(2):L445-51 (Pubitemid 38129527)
65. Revermann M, Barbosa-Sicard E, Dony E, et al. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens 2009;27(2):322-331
66. Liu X, Li C, Falck JR, et al. Interaction of nitric oxide, 20-HETE, and EETs during functional hyperemia in whisker barrel cortex. Am J Physiol 2008;295(2):H619-31
67. Koerner IP, Zhang W, Cheng J, et al. Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front Biosci 2008;13:2833-2841 (Pubitemid 351589201)
68. Williams JM, Sharma M, Anjaiahh S, et al. Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier. Am J Physiol Renal Physiol 2007;293(2):F501-5 (Pubitemid 47358120)
69. Stark K, Dostalek M, Guengerich FP. Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. FEBS J 2008;275(14):3706-3717
70. Chen J, Chen JK, Falck JR, et al. Mitogenic activity and signaling mechanism of 2-(14,15- epoxyeicosatrienoyl)glycerol, a novel cytochrome p450 arachidonate metabolite. Mol Cell Biol 2007;27(8):3023-3034
71. Snider NT, Kornilov AM, Kent UM, Hollenberg PF. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther 2007;321(2):590-597 (Pubitemid 46624513)
72. Awumey EM, Hill SK, Diz DI, Bukoski RD. Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries. Am J Physiol 2008;294(5):H2363-70
73. Catella F, Lawson JA, Fitzgerald DJ, Fitzgerald GA. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci USA 1990;87(15):5893-5897 (Pubitemid 20240395)
74. Hao CM, Breyer MD. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 2007;71(11):1105-1115 (Pubitemid 46809137)
75. Sun P, Liu W, Lin DH, et al. Epoxyeicosatrienoic acid activates BK channels in the cortical collecting duct. J Am Soc Nephrol 2009;20(3):513-523
76. Minuz P, Jiang H, Fava C, et al. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 2008;51(5):1379-1385 (Pubitemid 351555953)
77. Certikova Chabova VK, Herbert J, Vaneckova I, et al. The Roles of Intrarenal 20-Hydroxyeicosatetraenoic and Epoxyeicosatrienoic Acids in the Regulation of Renal Function in Hypertensive Ren-2 Transgenic Rats. Kidney Blood Press Res 2008;30(5):335-346 (Pubitemid 47482067)
78. Nusing RM, Schweer H, Fleming I, et al. Epoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: dependence on cyclooxygenase and cell polarity. Am J Physiol Renal Physiol 2007;293(1):F288-98 (Pubitemid 47345029)
79. Huang H, Morisseau C, Wang J, et al. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol 2007;293(1):F342-9 (Pubitemid 47345035)
80. Wang D, DuBois RN. Measurement of eicosanoids in cancer tissues. Methods Enzymol 2007;433:27-50
81. Zagorac D, Jakovcevic D, Gebremedhin D, Harder DR. Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. J Cereb Blood Flow Metab 2008;28(8):1431-1439
82. Jiang JG, Chen CL, Card JW, et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 2005;65(11):4707-4715 (Pubitemid 40740807)
83. Chen C, Li G, Liao W, et al. Selective inhibitors of CYP2J2 related to terfenadine exhibit activity strongly against human cancers in vitro and in vivo. J Pharmacol Exp Ther 2009, DOI: 10.1124/jpet.109.152017
84. Webler AC, Michaelis UR, Popp R, et al. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol 2008;295(5):C1292-301 (Pubitemid 352790340)
85. Webler AC, Popp R, Korff T, et al. Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4. Arterioscler Thromb Vasc Biol 2008;28(6):1123-1129
86. Smith HE, Jones JP 3rd, Kalhorn TF, et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008;18(11):943-953
87. Kirchheiner J, Meineke I, Fuhr U, et al. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 2008;9(3):277-288 (Pubitemid 351816765)
88. Jones J, Katayama J, Jiang Y, et al. Identification of danazol as a selectuve inhibitor of cytochrome P450 2J2. Drug Metab Rev 2008;78-79
89. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001;29(3):242-251 (Pubitemid 32179522)
90. Zordoky BNM, Aboutabl ME, El-Kadi AOS. Modulation of Cytochrome P450 Gene Expression and Arachidonic Acid Metabolism during Isoproterenol-Induced Cardiac Hypertrophy in Rats. Drug Metab Dispos 2008;36:2277-2286
91. Sura P, Sura R, Enayetallah AE, Grant DF. Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem 2008;56(6):551-559 (Pubitemid 351702299)
92. Thum T, Erpenbeck VJ, Moeller J, et al. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 2006;114(11):1655-1661 (Pubitemid 44718269)
93. Scarborough PE, Ma J, Qu W, Zeldin DC. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 1999;31(1):205-234 (Pubitemid 29106659)
94. Yu Z, Huse LM, Adler P, et al. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 2000;57(5):1011-1020 (Pubitemid 30253386)
95. Rowland-Yeo K, Rostami-Hodjean A, Tucker GT. Abundance of cytochrome P450 in human liver: a meta-analysis. Br J Clin Pharmacol 2005;106:97-132
96. Choudhary D, Jansson I, Stoilov I, et al. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 2004;32(8):840-847 (Pubitemid 38955614)
97. Karara A, Dishman E, Blair I, et al. Endogenous epoxyeicosatrienoic acids. Cytochrome P-450 controlled stereoselectivity of the hepatic arachidonic acid epoxygenase. J Biol Chem 1989;264(33):19822-19827 (Pubitemid 20008093)
98. Yue H, Jansen SA, Strauss KI, et al. A liquid chromatography/mass spectrometric method for simultaneous analysis of arachidonic acid and its endogenous eicosanoid metabolites prostaglandins, dihydroxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and epoxyeicosatrienoic acids in rat brain tissue. J Pharm Biomed Anal 2007;43(3):1122-1134 (Pubitemid 46185820)
99. Zeldin DC, Foley J, Boyle JE, et al. Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 1997;138(3):1338-1346 (Pubitemid 27089795)
100. Zeldin DC, Moomaw CR, Jesse N, et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996;330(1):87-96 (Pubitemid 26166628)
101. Zeldin DC, Foley J, Goldsworthy SM, et al. CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol 1997;51(6):931-943 (Pubitemid 27249126)
102. Yang S, Lin L, Chen JX, et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/ Akt signaling pathways. Am J Physiol 2007;293(1):H142-51